Validation of the Laryngeal Cognitive-affective Tool in a Taiwanese Population - PubMed (original) (raw)

. 2024 Dec 4:10.1097/MCG.0000000000002116.

doi: 10.1097/MCG.0000000000002116. Online ahead of print.

Affiliations

Validation of the Laryngeal Cognitive-affective Tool in a Taiwanese Population

Amanda J Krause et al. J Clin Gastroenterol. 2024.

Abstract

Background and aim: The laryngeal cognitive-affective tool (LCAT) was recently validated in the US to assess laryngeal-specific hypervigilance and anxiety. The aim of this study was to examine LCAT validity in the Taiwanese population.

Methods: This prospective single-center study enrolled adults from Hualien Tzu Chi Hospital with laryngeal symptoms for >6 months.

Results: One hundred four patients included: mean age 49.5 years (SD 13.3), 69% female, mean BMI 25.3 kg/m2 (5.8), and mean LCAT 25.9 (15.2). The LCAT had excellent internal consistency (α=0.969) and split-half reliability (Guttman=0.925).

Conclusions: The LCAT is newly validated in the Taiwanese population and assesses laryngeal-specific cognitive-affective processes in patients with chronic laryngeal symptoms.

Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest:

AJK, CC, MW, MG, EW: No disclosures

TT: Abyle Health (Consultant, Advisory Board), Takeda (Consultant), Healthline (Consultant)

PW: FemtoVox (Consultant)

JEP: AlfaSigma (Consultant); Endogastric solutions (Consultant, Speakers Bureau); Ethicon/ J&J (Advisory Committee/Board Member, Consultant, Speakers Bureau); Medtronic (Advisor or Review Panel Member, Consultant, Intellectual Property/Patents, Royalties, Speakers Bureau); Phathom (Consultant); Takeda (Consultant, Speakers Bureau)

CPG: Diversatek (Consultant, Grant/Research Support); Medtronic (Consultant)

RY: Consultant for Medtronic, Phathom Pharmaceuticals, StatLinkMD, Reckitt Benckiser Healthcare Ltd, Medscape; Research Support: Ironwood Pharmaceuticals; Advisory Board with Stock Options: RJS Mediagnostix

References

    1. Chen JW, Vela MF, Peterson KA, Carlson DA. AGA Clinical Practice Update on the Diagnosis and Management of Extraesophageal Gastroesophageal Reflux Disease: Expert Review. Clin Gastroenterol Hepatol. Jun 2023;21(6):1414–1421.e3. doi: 10.1016/j.cgh.2023.01.040 -DOI -PubMed
    1. Yadlapati R, Gyawali CP, Pandolfino JE, Participants CGCC. AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review. Clin Gastroenterol Hepatol. May 2022;20(5):984–994.e1. doi: 10.1016/j.cgh.2022.01.025 -DOI -PMC -PubMed
    1. Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. January 01 2022;117(1):27–56. doi: 10.14309/ajg.0000000000001538 -DOI -PMC -PubMed
    1. Liu K, Krause A, Yadlapati R. Quality of Life and Laryngopharyngeal Reflux. Dig Dis Sci. Jul 06 2023;doi: 10.1007/s10620-023-08027-8 -DOI -PMC -PubMed
    1. Wong MW, Hsiao SH, Wang JH, et al. Esophageal Hypervigilance and Visceral Anxiety Contribute to Symptom Severity of Laryngopharyngeal Reflux. Am J Gastroenterol. May 01 2023;118(5):786–793. doi: 10.14309/ajg.0000000000002151 -DOI -PubMed

Grants and funding

LinkOut - more resources